Skip to main content
Springer Nature Link
Log in

Preparation of meglumine antimonate loaded albumin nanoparticles and evaluation of its anti-leishmanial activity: an in vitro assay

  • Original Article
  • Published:
Journal of Parasitic Diseases Aims and scope Submit manuscript

Abstract

Cutaneous leishmaniasis is still a health problem worldwide, especially in tropical and subtropical areas. Currently, pentavalent antimony compounds are used to treat leishmaniasis. These compounds cause various side effects in the body. Therefore, there is a need to discover new drugs with less toxicity and more therapeutic effects. In this study, we encapsulated the meglumine antimonate into the albumin as a drug carrier and evaluated the anti-leishmanial effect of the prepared nanoparticles. The precipitation method was used for this purpose by applying different concentrations of glutaraldehyde and N-(3-Dimethylaminopropyl)-N-ethyl carbodiimide hydro chloride Ethyl (DEC) and then, field emission test was performed using Scanning Electron Microscopy for evaluating the morphology and size particles. The cytotoxicity and inhibitory of drugs were evaluated on J774 macrophages and Leishmania major promastigotes, respectively. Nanodrugs prepared using glutaraldehyde (10 μl/ml) and DEC (13 mg/ml) had the smallest and largest size, respectively. The highest anti-leishmanial activity was observed in the drugs prepared with glutaraldehyde (10 μl/ml). Also this nanodrug had the lowest cytotoxicity against macrophages. Given that meglumine antimonate loaded albumin nanoparticles prepared with glutaraldehyde (10 μg/ml), can improve the anti-leishmanial effects of this old drug, it can be a good option as a drug delivery system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  • Ahsan F, Rivas IP, Khan MA, Torres Suarez AI (2002) Targeting to macrophages: role of physicochemical properties of particulate carriers—liposomes and microspheres—on the phagocytosis by macrophages. J Control Release 79:29–40

    Article  PubMed  CAS  Google Scholar 

  • Benita S (2006) Microencapsulation methods and industrial applications. CRC Press, Boca Raton

    Google Scholar 

  • Borborema SE, Schwendener RA, Osso JA Jr, de Andrade HF Jr, do Nascimento N (2011) Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages. Int J Antimicrob Agents 38:341–347

    Article  PubMed  CAS  Google Scholar 

  • Chowdhary SJ, Chowdhary A, Kashaw S (2016) Macrophage targeting: a strategy for leishmaniasis specific delivery. Int J Pharm Pharm Sci 8:16–26

    CAS  Google Scholar 

  • Dandagi PM, Mastiholimath VS, Patil MB, Gupta MK (2006) Biodegradable microparticulate system of captopril. Int J Pharm 307:83–88

    Article  PubMed  CAS  Google Scholar 

  • Das S, Khan W, Mohsin Sh, Kumar N (2011) Miltefosine loaded albumin microparticles for treatment of visceral leishmaniasis: formulation development and in vitro evaluation. Polym Adv Technol 22:172–179

    Article  CAS  Google Scholar 

  • Date AA, Joshi MD, Patravale VB (2007) Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 59:505–521

    Article  PubMed  CAS  Google Scholar 

  • Desjeux P (1992) Human leishmaniases: epidemiology and public health aspects. World Health Stat Q 45:267–275

    PubMed  CAS  Google Scholar 

  • Elzoghby AO, Samy WM, Elgindy NA (2012) Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 157:168–182

    Article  PubMed  CAS  Google Scholar 

  • Fouladvand M, Barazesh A, Farokhzad F, Malekizadeh H, Sartavi K (2011) Evaluation of invitro anti-leishmanial activity of some brown, green and red algae from the Persian Gulf. Eur Rev Med Pharmacol Sci 15:597–600

    PubMed  CAS  Google Scholar 

  • Fouladvand M, Barazesh A, Tahmasebi R (2013) Evaluation of in vitro antileishmanial activity of curcumin and its derivatives “gallium curcumin, Indium curcumin and diacetyle curcumin”. Eur Rev Med Pharmacol Sci 17:3306–3308

    PubMed  CAS  Google Scholar 

  • Gour JK, Srivastava A, Kumar V, Bajpai S, Kumar H, Mishra M (2009) Nanomedicine and leishmaniasis: future prospects. Dig J Nanomater Biostruct 4:495–499

    Google Scholar 

  • Grinberg O, Hayun M, Sredni B, Gedanken A (2007) Characterization and activity of sonochemically-prepared BSA microspheres containing Taxol–an anticancer drug. Ultrason Sonochem 14:661–666

    Article  PubMed  CAS  Google Scholar 

  • Gupta PK, Hung CT (1989) Albumin microspheres: applications in drug delivery. J Microencapsul 6:463–472

    Article  PubMed  CAS  Google Scholar 

  • Jithan A, Madhavi K, Madhavi M, Prabhakar K (2011) Preparation and characterization of albumin nanoparticles encapsulating curcumin intended for the treatment of breast cancer. Int J Pharm Invest 1:119–125

    Article  CAS  Google Scholar 

  • Khan W, Kumar N (2011) Drug targeting to macrophages using paromomycin-loaded albumin microspheres for treatment of visceral leishmaniasis: an in vitro evaluation. J Drug Target 19:239–250

    Article  PubMed  CAS  Google Scholar 

  • Kouchakzadeh H, Shojaosadati SA, Shokri F (2014) Efficient loading and entrapment of tamoxifen in human serum albumin based nanoparticulate delivery system by a modified desolvation technique. Chem Eng Res Des 92:1681–1692

    Article  CAS  Google Scholar 

  • Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171–183

    Article  PubMed  CAS  Google Scholar 

  • Miele E, Spinelli GP, Miele E, Tomao F, Tomao S (2009) Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 4:99–105

    PubMed  PubMed Central  CAS  Google Scholar 

  • Nejati J, Mojadam M, Hanafi Bojd AA, Keyhani A, Habibi Nodeh F (2014) An epidemiological study of cutaneous leishmaniasis in Andimeshk (2005–2010). SJIMU 21:94–101

    Google Scholar 

  • Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, Modabber F (2009) Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 27:4747–4753

    Article  PubMed  CAS  Google Scholar 

  • Paul M, Durand R, Boulard Y, Fusaï T, Fernandez C, Rivollet D, Deniau M, Astier A (1998) Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. J Drug Target 5:481–490

    Article  PubMed  CAS  Google Scholar 

  • Peters T (1995) All about albumin. Biochemistry, genetics and medical applications. Academic press, San Diego

    Google Scholar 

  • Reithinger R, Dujardin J, Louzir H, Pirmez C, Alexander B, Brooker S (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7:581–596

    Article  PubMed  Google Scholar 

  • Sabur A, Ali N (2015) Vaccine biology of Leishmania infection. In: Adak S, Datta R (eds) Leishmania, current biology and control. Caister Academic Press, Norfolk, pp 167–192

    Chapter  Google Scholar 

  • Sanchez-Brunete JA, Dea MA, Rama S, Bolas F, Alunda JM, Raposo R, Mendez MT, Torrado-Santiago S, Torrado JJ (2004) Treatment of experimental visceral leishmaniasis with amphotericin-B in stable albumin microspheres. Antimicrob Agents Chemother 48:3246–3252

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Sanchez-Brunete JA, Dea MA, Rama S, Bolas F, Alunda JM, Torrado-Santiago S, Torrado JJ (2005) Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin-B. J Drug Target 13:225–233

    Article  PubMed  CAS  Google Scholar 

  • Santos DO, Coutinho CER, Madeira MF, Bottino CG, Vieira RT, Nascimento SB, Bernardino A, Bourguignon SC, Corte-Real S, Pinho RT, Rodrigues CR, Castro HC (2008) Leishmaniasis treatment—a challenge that remains: a review. Parasitol Res 103:1–10

    Article  PubMed  Google Scholar 

  • Schafer V, von Briesen H, Rubsamen-Waigmann H, Steffan AM, Royer C, Kreuter J (1994) Phagocytosis and degradation of human serum albumin microspheres and nanoparticles in human macrophages. J Microencapsul 11:261–269

    Article  PubMed  CAS  Google Scholar 

  • Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the indian epidemic. Clin Infect Dis 31:1104–1107

    Article  PubMed  CAS  Google Scholar 

  • Veerareddy PR, Vobalaboina V, Nahid A (2004) Formulation and evaluation of oil-in-water emulsions of piperine in visceral leishmaniasis. Pharmazie 59:194–197

    PubMed  CAS  Google Scholar 

  • Veerareddy PR, Vobalaboina V, Ali N (2009) Antileishmanial activity, pharmacokinetics and tissue distribution studies of mannosegrafted amphotericin-B lipid nanospheres. J Drug Target 17:140–147

    Article  PubMed  CAS  Google Scholar 

  • Venier-Julienne MC, Vouldoukis I, Monjour L, Benoit JP (1995) In vitro study of the anti-leishmanial activity of biodegradable nanoparticles. J Drug Target 3:23–29

    Article  PubMed  CAS  Google Scholar 

  • Wissing SA, Kayser O, Muller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–1272

    Article  PubMed  CAS  Google Scholar 

  • World Health Organization (1995) WHO model prescribing information: drugs used in parasitic diseases, 2nd edn. World Health Organization, Geneva. http://www.who.int/iris/handle/10665/41765

Download references

Acknowledgements

This research is a part of the project approved by the Vice-Chancellor for Research of Shiraz University of Medical Sciences at Grant Number: 95-01-01-12795. Therefore, the authors express their gratitude and thanks to the approval and financial support of this plan.

Author information

Authors and Affiliations

  1. Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

    Afshin Barazesh, Mohammad Hossein Motazedian & Sajad Rashidi

  2. Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Naghmeh Sattarahmady

  3. Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

    Mohammad Hossein Morowvat

  4. Department of Microbiology and Parasitology, Faculty of Medicine, Bushehr University of Medical Sciences, Moallem Street, P. O. Box 3631, Bushehr, Iran

    Afshin Barazesh

Authors
  1. Afshin Barazesh
    View author publications

    Search author on:PubMed Google Scholar

  2. Mohammad Hossein Motazedian
    View author publications

    Search author on:PubMed Google Scholar

  3. Naghmeh Sattarahmady
    View author publications

    Search author on:PubMed Google Scholar

  4. Mohammad Hossein Morowvat
    View author publications

    Search author on:PubMed Google Scholar

  5. Sajad Rashidi
    View author publications

    Search author on:PubMed Google Scholar

Contributions

Designed and performed the study: MHM; Nanoparticles syntesis: AB, NS, MHM; Performed the cell culture, anti-leishmanial assays and data analysis: AB, SR; Participated in writing the final paper: A B, MHM.

Corresponding authors

Correspondence to Afshin Barazesh or Mohammad Hossein Motazedian.

Ethics declarations

Conflict of interest

Authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barazesh, A., Motazedian, M.H., Sattarahmady, N. et al. Preparation of meglumine antimonate loaded albumin nanoparticles and evaluation of its anti-leishmanial activity: an in vitro assay. J Parasit Dis 42, 416–422 (2018). https://doi.org/10.1007/s12639-018-1018-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12639-018-1018-7

Keywords

Profiles

  1. Mohammad Hossein Morowvat View author profile